Tallac Therapeutics

Tallac Therapeutics is an innovative, clinical-stage biotech pioneering a novel class of immunostimulatory antibody-drug conjugates (ADCs). The company's TRAAC platform conjugates oligonucleotide payloads, like TLR9 agonists, to antibodies, aiming to precisely deliver immune-activating signals to the tumor while minimizing systemic toxicity. With two programs in the clinic, including lead candidate TAC-001 which has received FDA Fast Track designation, Tallac is advancing a pipeline designed to harness both innate and adaptive immunity against cancer. The company is privately held, founded in 2019, and based in San Mateo, California.

Proprietary platform for creating Toll-like Receptor Agonist Antibody Conjugates (TRAACs), enabling precise conjugation of oligonucleotide payloads (e.g., TLR9 agonists) to antibodies for targeted immune activation in the tumor microenvironment.

Tallac competes in the emerging field of immunostimulatory ADCs with companies like Silverback Therapeutics (now part of Gilead), Bolt Biotherapeutics, and others developing TLR or STING agonist conjugates. It differentiates with its specific focus on a potent TLR9 agonist payload and a proprietary conjugation technology for oligonucleotides.